The medium-sized biopharma is showing off new results from dordaviprone and Zepzelca, both of which were acquired through ...

Despite mixed results, analysts maintained faith in ivonescimab’s ability to cross over between Eastern and Western patient ...

Keros will be down to 85 full-time employees after the layoffs and expects to generate annualized savings of $17 million.

Although the FDA has rejected Stealth’s new drug application for Barth syndrome candidate elamipretide, the agency identified ...

At the heart of the deal is an anti-Claudin18.2 antibody-drug conjugate being developed for solid tumors, including gastric ...

The National Legal and Policy Center, a right-wing advocacy and watchdog group, had asked the company to revisit its DEI ...

Analysts at Truist Securities admitted that the result for itepekimab, which the companies were hoping to follow their ...

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

According to the nonprofit news outlet NOTUS, at least seven studies cited in the Make America Healthy Again report released ...

In a letter to the Department of Commerce, Novo Nordisk argued that unsanctioned compounded semaglutide, mostly from China, ...

Teos expects to absorb nearly $25 million in one-time costs for severance and termination payments. The biotech had 173 ...

The canceled contract comes as Moderna nears a critical FDA decision for its next-generation COVID-19 vaccine.